映恩生物（09606）于2026年2月5日发布截至2026年1月31日的股份变动月报表。报告显示，公司法定股本维持在200,000,000股，面值每股0.0001美元，注册股本总额20,000美元，期间无变化。
报告期内，已发行普通股由月初的89,415,414股增至月末的90,137,714股，增幅为722,300股。该新增股份源自首次公开发售前股权激励计划的行使，合计募资约2,254,833.7港元。公司并未进行任何股份回购、注销或库存股份变动。
截至2026年1月31日，公司已发行股本总数上升至90,137,714股。映恩生物确认继续符合香港联交所规定的最低公众持股量要求。根据公告披露，此报告由联席公司秘书袁佳丽签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.